4 results about "Clostridium difficile infections" patented technology

Antibody-based binding agents derived from human and camelid immunoglobulins are described, as well as strains of yeast engineered to secrete the binding agents, and methods of treating and preventing Clostridium difficile infections using the engineered strains of yeast. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and / or toxin B and in some cases exhibit toxin neutralizing activity. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.

The present application provides the use of a nanocomposite with a core-shell structure. Specifically, the present application provides the use of a nanocomposite with a core-shell structure in the preparation of a drug for preventing and / or treating Clostridium difficile infection and recurrent diseases caused thereby, wherein the nanocomposite comprises: ZnO nanoparticles as a core; mesoporous silica as a shell coated on the surface of the ZnO nanoparticles; an antibiotic loaded in the pore channel of the mesoporous silica; hyperbranched polylysine modified on the surface of the mesoporous silica; and a pH-responsive coating material as the outermost layer. The nanocomposite provided by the present application can achieve precise targeted release of the drug in the colon, and through the sequential and synergistic mechanism of "membrane breaking-sterilization-spore inhibition-repair", it can simultaneously solve multiple factors leading to CDI recurrence such as biofilm protection, spore storage, bacterial population destruction, mucosal damage, etc., and improve the treatment effect.

Disclosed are vaccine compositions comprising polypeptides selected from Closlridioides difficile binary' toxin B, Closlridioides difficile binary toxin A, a High Molecular Weight portion of Closlridioides difficile Surface Layer Protein A, and a Low Molecular Weight portion of Closlridioides difficile Surface Layer Protein A. Methods of preparing the vaccine composition, methods of preventing or reducing attachment of C. difficile to an epithelial cell, and methods of preventing or treating a condition caused by infection of Closlridioides difficile are also provided.